Patents by Inventor Aptalis Pharma Canada Inc.

Aptalis Pharma Canada Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140017223
    Abstract: The present invention provides for pharmaceutical compositions comprising pancreatic enzyme preparations (PEPs) with viral infectivity reduced below significant levels and having high enzymatic activity. The PEPs can comprise lipases, proteases, amylases, non-enveloped viruses (e.g., porcine parvovirus (PPV), porcine circovirus type 2 (PCV-2), porcine encephalomyocarditis virus (EMCV)), and enveloped viruses (e.g., vesicular stomatitis virus (VSV), and influenza A (IFA)). The present invention also includes methods of treating pancreatic insufficiency by administering these pharmaceutical compositions and methods of making the same by treating the PEP with beta-propiolactone (BPL) to reduce viral infectivity.
    Type: Application
    Filed: May 1, 2013
    Publication date: January 16, 2014
    Applicant: Aptalis Pharma Canada Inc.
    Inventor: Aptalis Pharma Canada Inc.
  • Publication number: 20130338086
    Abstract: Disclosed herein are methods for separating ionic impurities from monosaccharide processing streams using simulated moving bed chromatography.
    Type: Application
    Filed: January 7, 2013
    Publication date: December 19, 2013
    Applicant: Aptalis Pharma Canada Inc.
    Inventor: Aptalis Pharma Canada Inc.
  • Publication number: 20130337062
    Abstract: The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes.
    Type: Application
    Filed: May 1, 2013
    Publication date: December 19, 2013
    Applicant: Aptalis Pharma Canada Inc.
    Inventor: Aptalis Pharma Canada Inc.